Precision BioSciences Q1 Earnings Report Analysis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy DTIL?
Source: seekingalpha
- Earnings Performance: Precision BioSciences reported a Q1 GAAP EPS of -$0.75, missing expectations by $0.09, indicating challenges in profitability that may affect investor confidence.
- Revenue Growth: The company achieved Q1 revenue of $10.84M, a significant increase from $29K year-over-year, beating market expectations by $6.79M, demonstrating substantial progress in the commercialization of its gene editing technologies.
- Cash Reserves: As of March 31, 2026, Precision BioSciences holds a cash balance of $125.8M, including cash, cash equivalents, and restricted cash, providing financial stability for future clinical stage gene editing projects.
- Project Milestones: The company anticipates utilizing its cash reserves to support data milestones for its two wholly owned clinical stage gene editing programs, PBGENE-HBV and PBGENE-DMD, through 2028, reflecting the sustainability of its long-term strategic vision.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DTIL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DTIL
Wall Street analysts forecast DTIL stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 7.480
Low
30.00
Averages
45.00
High
60.00
Current: 7.480
Low
30.00
Averages
45.00
High
60.00
About DTIL
Precision BioSciences, Inc. is a clinical-stage gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The Company's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is its lead in vivo gene editing program designed to eliminate cccDNA, the key source of replicating hepatitis B virus (HBV) and inactivating integrated HBV DNA in hepatocytes. Its PBGENE-3243 program is a first of its kind potential treatment for m.3243 associated mitochondrial disease. The Company's iECURE-OTC program is developed in partnership with iECURE, Inc.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Precision BioSciences Q1 Earnings Report Analysis
- Earnings Performance: Precision BioSciences reported a Q1 GAAP EPS of -$0.75, missing expectations by $0.09, indicating challenges in profitability that may affect investor confidence.
- Revenue Growth: The company achieved Q1 revenue of $10.84M, a significant increase from $29K year-over-year, beating market expectations by $6.79M, demonstrating substantial progress in the commercialization of its gene editing technologies.
- Cash Reserves: As of March 31, 2026, Precision BioSciences holds a cash balance of $125.8M, including cash, cash equivalents, and restricted cash, providing financial stability for future clinical stage gene editing projects.
- Project Milestones: The company anticipates utilizing its cash reserves to support data milestones for its two wholly owned clinical stage gene editing programs, PBGENE-HBV and PBGENE-DMD, through 2028, reflecting the sustainability of its long-term strategic vision.
See More
Precision BioSciences to Announce Q1 Earnings on May 5
- Earnings Announcement Schedule: Precision BioSciences is set to release its Q1 2023 earnings report on May 5 before market open, with a consensus EPS estimate of -$0.81, reflecting a 63.3% year-over-year improvement, indicating efforts towards enhancing profitability.
- Revenue Expectations: Analysts forecast revenue of $4.05 million for the quarter, although the company has only beaten revenue estimates 25% of the time over the past year, suggesting ongoing challenges in revenue growth.
- Historical Performance Review: Over the past year, Precision BioSciences has exceeded EPS estimates 75% of the time, demonstrating relative stability in earnings forecasts, which may bolster investor confidence ahead of the upcoming report.
- Market Reaction Anticipation: As the earnings report approaches, investors will closely monitor the company's performance, particularly in the current economic climate, where any results exceeding expectations could positively impact the stock price.
See More
Precision BioSciences Launches DMD Clinical Trial at Arkansas Children's Hospital
- Clinical Trial Launch: Precision BioSciences has activated the FUNCTION-DMD clinical trial at Arkansas Children's Hospital, now enrolling patients, marking a significant advancement in the treatment of Duchenne muscular dystrophy (DMD) and potentially offering new therapeutic options for patients.
- Trial Design and Objectives: The FUNCTION-DMD study aims to enroll ambulatory patients aged 2-7 with mutations between exons 45 and 55, representing approximately 60% of boys with DMD, to evaluate safety, tolerability, and efficacy, potentially providing durable muscle function improvements.
- Multidisciplinary Care Center: Arkansas Children's Hospital, recognized as a PPMD-certified Duchenne Care Center, delivers specialized multidisciplinary care, ensuring high standards in clinical services while providing comprehensive support for patients participating in the FUNCTION-DMD study.
- FDA Special Designations: PBGENE-DMD has received Orphan Drug Designation and Fast Track designation from the FDA, highlighting its potential in treating DMD and likely leading to significant functional improvements for patients, thereby enhancing Precision BioSciences' leadership in the gene editing sector.
See More
Precision BioSciences Grants RSUs to New Employee
- Employee Incentive Plan: On April 20, 2026, Precision BioSciences approved the grant of 7,094 restricted stock units (RSUs) to a new employee as an inducement award, aimed at attracting high-quality talent to the company.
- Grant Conditions: Under Nasdaq Listing Rule 5635(c)(4), the RSUs will vest in substantially equal annual installments on each of the first three anniversaries of the employee's start date, ensuring continued service and contribution to the company.
- ARCUS Platform Advantages: Precision BioSciences' ARCUS gene editing platform, with its unique cutting mechanism and smaller structure, is dedicated to developing gene editing therapies for high unmet need diseases, showcasing significant market potential.
- Diverse Treatment Approaches: The platform supports various gene editing strategies, including gene elimination, defective gene excision, and gene insertion, aimed at providing lasting cures for a broad range of genetic and infectious diseases, further solidifying the company's position in the industry.
See More
Precision BioSciences Presents New Hepatitis Treatment Data
- Clinical Trial Progress: Precision BioSciences will present new clinical biopsy data from the ELIMINATE-B trial at the 2026 EASL Congress, demonstrating for the first time that PBGENE-HBV can eliminate cccDNA in the livers of chronic hepatitis B patients, marking a significant breakthrough that may offer hope for a cure.
- Therapeutic Potential: PBGENE-HBV is the world's first clinical trial targeting cccDNA through gene editing, designed to eliminate the root cause of chronic hepatitis B, and has received Fast Track designation from the FDA, highlighting its potential importance in treatment.
- Conference Highlights: The study will be showcased in a poster presentation on May 27, 2026, with abstract number LB26-51656, expected to attract significant attention and potentially boost investor confidence in the company's future developments.
- Market Outlook: Given the urgent need for effective treatments among chronic hepatitis B patients, the success of PBGENE-HBV could significantly enhance Precision BioSciences' competitiveness in the biopharmaceutical market, further solidifying its leadership position in the gene editing field.
See More
Precision BioSciences Expands ELIMINATE-B Trial into France and Romania
- Clinical Trial Expansion: Precision BioSciences has received Clinical Trial Application approval to expand the ELIMINATE-B trial into France and Romania, which is expected to significantly increase patient enrollment and support the clinical execution of PBGENE-HBV.
- Global Footprint Enhancement: This expansion adds multiple clinical trial sites in Europe to the ELIMINATE-B trial, including the UK, Moldova, New Zealand, and the US, thereby enhancing the company's international presence and influence.
- Increased Treatment Potential: PBGENE-HBV is the first gene editing therapy specifically designed to eliminate the root cause of chronic hepatitis B, cccDNA, and is expected to offer patients a potential cure, fundamentally changing the treatment landscape for chronic hepatitis B.
- Strong Investigator Interest: The late breaker oral presentation of PBGENE-HBV at The Liver Conference 2025 generated significant interest, and the new trial sites are anticipated to further drive investigator engagement and the success of the clinical trial.
See More
Precision BioSciences Q1 Earnings Report Analysis
- Earnings Performance: Precision BioSciences reported a Q1 GAAP EPS of -$0.75, missing expectations by $0.09, indicating challenges in profitability that may affect investor confidence.
- Revenue Growth: The company achieved Q1 revenue of $10.84M, a significant increase from $29K year-over-year, beating market expectations by $6.79M, demonstrating substantial progress in the commercialization of its gene editing technologies.
- Cash Reserves: As of March 31, 2026, Precision BioSciences holds a cash balance of $125.8M, including cash, cash equivalents, and restricted cash, providing financial stability for future clinical stage gene editing projects.
- Project Milestones: The company anticipates utilizing its cash reserves to support data milestones for its two wholly owned clinical stage gene editing programs, PBGENE-HBV and PBGENE-DMD, through 2028, reflecting the sustainability of its long-term strategic vision.
See More
Precision BioSciences to Announce Q1 Earnings on May 5
- Earnings Announcement Schedule: Precision BioSciences is set to release its Q1 2023 earnings report on May 5 before market open, with a consensus EPS estimate of -$0.81, reflecting a 63.3% year-over-year improvement, indicating efforts towards enhancing profitability.
- Revenue Expectations: Analysts forecast revenue of $4.05 million for the quarter, although the company has only beaten revenue estimates 25% of the time over the past year, suggesting ongoing challenges in revenue growth.
- Historical Performance Review: Over the past year, Precision BioSciences has exceeded EPS estimates 75% of the time, demonstrating relative stability in earnings forecasts, which may bolster investor confidence ahead of the upcoming report.
- Market Reaction Anticipation: As the earnings report approaches, investors will closely monitor the company's performance, particularly in the current economic climate, where any results exceeding expectations could positively impact the stock price.
See More
Precision BioSciences Launches DMD Clinical Trial at Arkansas Children's Hospital
- Clinical Trial Launch: Precision BioSciences has activated the FUNCTION-DMD clinical trial at Arkansas Children's Hospital, now enrolling patients, marking a significant advancement in the treatment of Duchenne muscular dystrophy (DMD) and potentially offering new therapeutic options for patients.
- Trial Design and Objectives: The FUNCTION-DMD study aims to enroll ambulatory patients aged 2-7 with mutations between exons 45 and 55, representing approximately 60% of boys with DMD, to evaluate safety, tolerability, and efficacy, potentially providing durable muscle function improvements.
- Multidisciplinary Care Center: Arkansas Children's Hospital, recognized as a PPMD-certified Duchenne Care Center, delivers specialized multidisciplinary care, ensuring high standards in clinical services while providing comprehensive support for patients participating in the FUNCTION-DMD study.
- FDA Special Designations: PBGENE-DMD has received Orphan Drug Designation and Fast Track designation from the FDA, highlighting its potential in treating DMD and likely leading to significant functional improvements for patients, thereby enhancing Precision BioSciences' leadership in the gene editing sector.
See More
Precision BioSciences Grants RSUs to New Employee
- Employee Incentive Plan: On April 20, 2026, Precision BioSciences approved the grant of 7,094 restricted stock units (RSUs) to a new employee as an inducement award, aimed at attracting high-quality talent to the company.
- Grant Conditions: Under Nasdaq Listing Rule 5635(c)(4), the RSUs will vest in substantially equal annual installments on each of the first three anniversaries of the employee's start date, ensuring continued service and contribution to the company.
- ARCUS Platform Advantages: Precision BioSciences' ARCUS gene editing platform, with its unique cutting mechanism and smaller structure, is dedicated to developing gene editing therapies for high unmet need diseases, showcasing significant market potential.
- Diverse Treatment Approaches: The platform supports various gene editing strategies, including gene elimination, defective gene excision, and gene insertion, aimed at providing lasting cures for a broad range of genetic and infectious diseases, further solidifying the company's position in the industry.
See More
Precision BioSciences Presents New Hepatitis Treatment Data
- Clinical Trial Progress: Precision BioSciences will present new clinical biopsy data from the ELIMINATE-B trial at the 2026 EASL Congress, demonstrating for the first time that PBGENE-HBV can eliminate cccDNA in the livers of chronic hepatitis B patients, marking a significant breakthrough that may offer hope for a cure.
- Therapeutic Potential: PBGENE-HBV is the world's first clinical trial targeting cccDNA through gene editing, designed to eliminate the root cause of chronic hepatitis B, and has received Fast Track designation from the FDA, highlighting its potential importance in treatment.
- Conference Highlights: The study will be showcased in a poster presentation on May 27, 2026, with abstract number LB26-51656, expected to attract significant attention and potentially boost investor confidence in the company's future developments.
- Market Outlook: Given the urgent need for effective treatments among chronic hepatitis B patients, the success of PBGENE-HBV could significantly enhance Precision BioSciences' competitiveness in the biopharmaceutical market, further solidifying its leadership position in the gene editing field.
See More
Precision BioSciences Expands ELIMINATE-B Trial into France and Romania
- Clinical Trial Expansion: Precision BioSciences has received Clinical Trial Application approval to expand the ELIMINATE-B trial into France and Romania, which is expected to significantly increase patient enrollment and support the clinical execution of PBGENE-HBV.
- Global Footprint Enhancement: This expansion adds multiple clinical trial sites in Europe to the ELIMINATE-B trial, including the UK, Moldova, New Zealand, and the US, thereby enhancing the company's international presence and influence.
- Increased Treatment Potential: PBGENE-HBV is the first gene editing therapy specifically designed to eliminate the root cause of chronic hepatitis B, cccDNA, and is expected to offer patients a potential cure, fundamentally changing the treatment landscape for chronic hepatitis B.
- Strong Investigator Interest: The late breaker oral presentation of PBGENE-HBV at The Liver Conference 2025 generated significant interest, and the new trial sites are anticipated to further drive investigator engagement and the success of the clinical trial.
See More
